Patiromer

VELTASSA

Open Patiromer in the interactive console ↗

Pronunciation: pa-TIR-oe-mer

Patiromer ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Patiromer ballicule

Patiromer VELTASSA mascot mnemonic cartoon — Visual mnemonic: Patiromer mascot
**“Trades calcium for K+”**

What it isNon-absorbed potassium binder exchanging calcium for potassium; hyperkalemia.

Why this oneIt allows RAAS inhibitors to be continued in heart failure and CKD, which is usually the point of using it.

What limits itOnset takes about seven hours, so it is not for emergencies. It binds other drugs — separate by three hours; hypomagnesemia.

Patiromer molecular structure (skeletal formula) — Molecular structure: Patiromer

FDA label

Read the full label on DailyMed ↗

FDA dosing	Population	Start	Target	Max
Hyperkalemia	Adults	8.4 g QD	titrate by 8.4 g at ≥1-wk intervals	25.2 g QD
Hyperkalemia	Children 12–17 yr	4 g QD	titrate by 4 g at ≥1-wk intervals	25.2 g QD

Titration Adjust at 1-week or longer intervals

Renal No adjustment needed

Hepatic Undefined

Separate from other oral medications by at least 3 hours

Instructions

Take at least 3 hours before or after other oral medications (unless no clinically important interaction)
Do not heat (e.g., microwave) or add to heated foods/liquids
Do not take in dry form
Mix with water or soft food and drink/consume immediately

Available strengths

powder 1, 8.4, 16.8 g/packet
susp 1000, 8400, 16800, 25200 mg

Cautions

Worsening of GI motility — avoid in severe constipation, bowel obstruction, or impaction
Hypomagnesemia — monitor serum magnesium and consider supplementation

Adverse reactions

Constipation
Hypomagnesemia
Diarrhea
Nausea
Abdominal discomfort
Flatulence

Pregnancy Not absorbed systemically; maternal use not expected to result in fetal risk.

Lactation Not absorbed systemically; not expected to result in risk to the infant.

Cost

Patiromer (VELTASSA)

Strength		#/mo	CostPlus
1 g/packet	powder	per unit	not offered
8.4 g/packet	powder	per unit	not offered
16.8 g/packet	powder	per unit	not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Patiromer is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry2033 est.

NO BOXED WARNINGS

Principal riskSlow onset; binds other drugs, separate by three hours

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4

Overdose danger1 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk0 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.

Open Patiromer in the interactive console ↗